You keep hearing the names. Ozempic. Wegovy. Mounjaro. Maybe your doctor mentioned one. Maybe a friend lost forty pounds and casually dropped "I started a GLP-1" into conversation like it was nothing. Maybe you've been down a rabbit hole of TikTok videos at midnight, and now you're here, looking for something that doesn't feel like a sales pitch or a scare story.
Good. That's exactly why we wrote this.
So what actually is GLP-1?
GLP-1 stands for glucagon-like peptide-1. It's a hormone. Your body already makes it — every time you eat, your gut releases GLP-1 into your bloodstream. It does a few things at once: tells your pancreas to produce insulin, signals your brain that you're getting full, and slows down how quickly food leaves your stomach.
It's your body's natural "that's enough" signal.
The problem — and this is where it gets interesting — is that for millions of people, particularly those carrying significant extra weight, this signal doesn't fire strongly enough. The message gets lost. You eat, but the fullness doesn't land the way it should. The hunger stays. The thoughts about food keep circling.
GLP-1 medications are synthetic versions of this hormone, engineered to be dramatically more potent and longer-lasting than what your body produces naturally. They amplify the signal.
What people actually experience
The clinical language is "appetite suppression" and "reduced caloric intake." But that doesn't capture what people actually describe when they start these medications.
The phrase you'll hear most often in GLP-1 communities is "the food noise stopped." It comes up constantly — in forums, in doctor's offices, in conversations between friends. One user on a popular weight loss forum put it this way: after decades of constant mental chatter about food — what to eat next, guilt about what they just ate, planning meals while still finishing one — it just went quiet. Like someone turned off a radio they didn't know was playing.
That shift is, for many people, the most profound thing about these medications. Not the number on the scale. The silence.
Beyond the reduced appetite, most people also notice they feel full much faster during meals, they lose interest in specific cravings (particularly for high-sugar and high-fat foods), and their blood sugar stabilises — which translates to fewer energy crashes throughout the day.
The medications on the market right now
The GLP-1 landscape has expanded significantly in the past few years. Here's what's available as of early 2026:
Semaglutide is the active ingredient behind the biggest names. Ozempic (approved for type 2 diabetes in 2017) was the drug that started the cultural conversation, even though it wasn't originally approved for weight loss. Wegovy uses the same molecule at a higher dose and is specifically approved for chronic weight management. As of January 2026, Wegovy is also available as a daily oral pill — a significant development for people who prefer not to inject. Rybelsus is an older oral form approved for diabetes.
A critical development: semaglutide's US patent expired on March 20, 2026. Generic versions are now legally permitted, which is expected to bring prices down substantially over the coming months.
Tirzepatide is the newer contender and works differently. While semaglutide targets one receptor (GLP-1), tirzepatide targets two — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism appears to produce greater weight loss in clinical trials. Mounjaro is approved for type 2 diabetes; Zepbound is the same molecule approved specifically for weight loss.
In the landmark SURMOUNT-1 trial, tirzepatide produced average weight loss of up to 22.5% of body weight — results that rival what some people achieve with bariatric surgery (Jastreboff et al., 2022). When tested head-to-head against semaglutide in SURMOUNT-5, tirzepatide came out ahead: 20.2% versus 13.7% weight loss (Aronne et al., 2025).
What's coming next is equally compelling. Retatrutide, a triple receptor agonist from Eli Lilly, targets GLP-1, GIP, and glucagon simultaneously. Phase 2 trials showed weight loss approaching 29% of body weight. CagriSema, Novo Nordisk's combination of semaglutide with an amylin analogue, demonstrated roughly 20% weight loss in phase 3. An effective oral GLP-1 that doesn't require fasting before taking it is the holy grail many companies are chasing.
Who can take them?
These aren't vanity drugs. They're prescribed for specific clinical situations.
For weight loss, you generally need a BMI of 30 or above (clinical obesity), or a BMI of 27 or above with at least one weight-related health condition — high blood pressure, type 2 diabetes, high cholesterol, sleep apnoea, and similar. For type 2 diabetes, GLP-1 medications are prescribed as part of blood sugar management, often when earlier treatments haven't been sufficient.
About 41 million Americans have already used a GLP-1 medication — roughly one in eight adults. This isn't a niche treatment anymore. It's one of the most significant shifts in medicine in decades.
What you should know before starting
A few things that get glossed over in the marketing:
The side effects are real. Nausea is the most commonly reported — somewhere between 15% and 45% of users experience it, depending on the medication and dose. It's usually worst in the first few weeks and during dose increases, then tends to improve substantially. Constipation, diarrhoea, and fatigue are also common early on. Our full side effects guide covers every symptom and how to manage it.
Muscle loss is a legitimate concern. When you lose weight rapidly — by any method — some of that weight comes from lean mass. Data from the SURMOUNT-1 body composition substudy shows roughly 75% of weight lost on tirzepatide is fat, with 25% being lean mass (Look et al., 2025). This is why resistance training and adequate protein intake aren't optional extras — they're essential parts of treatment.
Weight tends to return when you stop. The STEP 1 trial extension found that participants regained approximately two-thirds of their lost weight within a year of stopping semaglutide (Wilding et al., 2022). This has led the medical community to increasingly view GLP-1 medications as long-term treatments for a chronic condition, rather than short courses with permanent results.
The cost has been brutal — but it's changing. List prices have historically exceeded $1,000 per month. However, manufacturer price cuts, expanded insurance coverage, and the arrival of generic semaglutide are all shifting the landscape rapidly in 2026.
The bigger picture
GLP-1 medications represent something genuinely new. Not a fad diet repackaged. Not another supplement with dubious claims. A class of drugs with robust clinical trial data, published in the world's most rigorous medical journals, demonstrating consistent, significant, reproducible weight loss alongside meaningful improvements in cardiovascular risk, blood sugar control, and metabolic health.
The SELECT trial showed that semaglutide reduced major cardiovascular events by 20% in people with obesity who didn't have diabetes (Lincoff et al., 2023). That finding alone reframed the entire conversation — this isn't about fitting into smaller clothes. It's about living longer.
But they aren't magic. They work best when combined with thoughtful nutrition (particularly adequate protein), regular exercise (particularly resistance training), adequate sleep, and ongoing medical supervision. They're a tool — arguably the most powerful tool we've ever had for weight management — but a tool that still requires your active participation.
If you're considering starting a GLP-1 medication, the best next step is a conversation with your healthcare provider about your specific situation, health history, and goals. And if you want to understand more before that conversation, keep reading. That's what this site is for.
Key Studies & References
We base this guide on the strongest available peer-reviewed research so you can see exactly where the information comes from. Here are the most relevant and impactful studies we referenced:
-
Jastreboff et al. (2022) — The landmark SURMOUNT-1 trial showing tirzepatide produced up to 22.5% body weight loss in adults with obesity, rivalling results seen with bariatric surgery. Read the full trial
-
Aronne et al. (2025) — The first major head-to-head trial (SURMOUNT-5) directly comparing tirzepatide to semaglutide, finding tirzepatide produced significantly greater weight loss: 20.2% versus 13.7%. Read the study on PubMed
-
Wilding et al. (2021) — The foundational STEP 1 trial demonstrating approximately 15% weight loss with semaglutide 2.4mg over 68 weeks, the study that led to Wegovy's approval. Read the full study
-
Wilding et al. (2022) — STEP 1 extension tracking what happens after stopping semaglutide: participants regained roughly two-thirds of lost weight within one year, shaping how doctors view these as long-term treatments. Read the study on PubMed
-
Lincoff et al. (2023) — The SELECT trial showing semaglutide reduced major cardiovascular events by 20% in people with obesity who didn't have diabetes — the study that reframed GLP-1 medications as cardiovascular treatments, not just weight loss drugs. Read the study on PubMed
-
Look et al. (2025) — Body composition substudy of SURMOUNT-1 using DXA scanning, confirming approximately 75% of weight lost on tirzepatide is fat mass with 25% lean mass — the key data point driving the emphasis on resistance training and protein intake. Read the study on PubMed
These studies represent the core clinical evidence behind modern GLP-1 treatment. Together, they show consistent, significant weight loss alongside meaningful metabolic and cardiovascular benefits — but also highlight that muscle preservation and long-term adherence remain important considerations.
Medical Disclaimer: GLP-1 medications are prescription drugs that require medical supervision. This guide is for informational purposes only — always consult your healthcare provider before starting or changing any medication.